Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

New England Journal of Medicine - United States
doi 10.1056/nejmoa1111065
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Massachusetts Medical Society

Related search

Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer

Journal of Breast Disease
2018English

Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer

Journal of Cancer Research and Clinical Oncology
MedicineCancer ResearchOncology
2013English

Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy With Zoledronic Acid for HER2-Negative Breast Cancer in Japan: The JONIE1 Study

Health
2019English

Comparative Analysis of Different Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer

Tumors of female reproductive system
2017English

Neoadjuvant Chemotherapy in Breast Cancer

English

Current Neoadjuvant Treatment Options for HER2 Positive Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2011English

Neoadjuvant Chemotherapy: Role in Breast Cancer

2013English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

Neoadjuvant Chemotherapy for Early Breast Cancer – Author's Reply

The Lancet Oncology
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy